Early-stage
J&J CAR-T Therapy Achieves 100% Response Rate in Early-Stage Lymphoma Trial
J&J; CAR-T therapy; lymphoma; early-stage; clinical trial; dual-targeting; CD19; CD20; objective response rate; Phase 1b; JNJ-4496; relapsed/refractory large B-cell lymphoma
Genmab Streamlines Portfolio by Cutting Early-Stage Oncology Assets
Genmab, oncology, early-stage candidates, portfolio optimization, Phase 3 projects
KdT Ventures Secures $100M Fourth Fund to Fuel Early-Stage Biotech Startups
KdT Ventures, $100M fund, early-stage startups, biotech, frontier science, life sciences investment
Merck Halts Two Phase 3 Trials of Keytruda for Early-Stage Lung and Skin Cancers
Merck, Keytruda, Phase 3 trials, early-stage lung cancer, skin cancer, KEYNOTE-867, KEYNOTE-630
Curie.Bio Raises $380M to Support Early-Stage Biotechs
Curie.Bio, biotech accelerator, venture capital, Series A rounds, early-stage biotechs, Alexis Borisy, Zach Weinberg
Biogen Discontinues Ionis Collaboration on ALS and Angelman Syndrome Treatments Following Early Clinical Results
Biogen, Ionis, ALS, Angelman Syndrome, collaboration, discontinuation, early-stage readouts, clinical trials, treatments, neurological disorders.
Biogen and Ionis Discontinue ALS Drug Development Following Unsuccessful Early Trials
Biogen, Ionis, ALS, drug development, early-stage trial, disappointing results, discontinuation, neurological disorder, treatment research.
Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC
Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines
FDA Approves BrainStorm’s Phase IIIb Trial Design for NurOwn in Early-Stage ALS
BrainStorm Cell Therapeutics, NurOwn, Phase IIIb trial, Special Protocol Assessment (SPA), FDA agreement, Early-stage ALS, Amyotrophic Lateral Sclerosis (ALS)